Considering that an actual or potential blockbuster developed by a smaller biotech is catnip to big pharma, obtaining a blockbuster by buying it might be expected to be the most common strategy. But according to data from Evaluate, only 81 companies with blockbusters gained them through dealmaking – at least when the parameters are limited to clinical stages.
Meanwhile, 105 drug companies either discovered blockbusters internally or bought them before clinical trials had started. Many companies that developed...
